Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study

References

• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128(2):739–745. doi:10.1378/chest.128.2.739
   PubMed Web of Science ®Google Scholar
• Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017
   PubMed Web of Science ®Google Scholar
• Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.
   PubMedGoogle Scholar
• Fjaellegaard K, Sin MD, Browatzki A, Ulrik CS. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review. Chron Respir Dis. 2017;14(2):174–186. doi:10.1177/1479972316661923
   PubMed Web of Science ®Google Scholar
• Mandal P, Hill AT. Bronchiectasis: breaking the cycle of inflammation and infection. Lancet Respir Med. 2013;1(1):2012–2013. doi:10.1016/S2213-2600(13)70005-5
   Google Scholar
• Chalmers JD, Boersma W, Lonergan M, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7(10):845–854. doi:10.1016/S2213-2600(19)30191-2
   PubMed Web of Science ®Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med. 2014;2(6):455–463. doi:10.1016/S2213-2600(14)70050-5
   PubMed Web of Science ®Google Scholar
• Lasserson TJ, Holt K, Milan SJ, Greenstone M. Oral corticosteroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev. 2001. doi:10.1002/14651858.CD002162
   Google Scholar
• Chalmers JD, Haworth CS, Metersky ML, et alL; WILLOW Investigators. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2020;383(22):2127–2137. doi:10.1056/NEJMoa2021713.
   Google Scholar
• Bateman ed ED, Hurd SS, Barnes PJ, et al.Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal. 2008;31(1):143–178. doi:10.1183/09031936.00138707.
   Google Scholar
• Halpin DM. Global Initiative for Chronic Obstructive Lung Disease. GOLD Report 2020. Glob Initiat Chronic Obstr Lung Dis. 2020.
   Google Scholar
• Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev. 2018;2018(5):485. doi:10.1002/14651858.CD000996.pub3
   Web of Science ®Google Scholar
• Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126(1):213–219. doi:10.1378/chest.126.1.213
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3
   PubMed Web of Science ®Google Scholar
• Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6). doi:10.1183/13993003.00051-2017
   PubMed Web of Science ®Google Scholar
• Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850–873. doi:10.1111/cea.12141
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index an international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585. doi:10.1164/rccm.201309-1575OC
   PubMed Web of Science ®Google Scholar
• Ip M, Lam WK, So SY, Liong E, Chan CY, Tse KM. Analysis of factors associated with bronchial hyperreactivity to methacholine in bronchiectasis. Lung. 1991;169(1):43–51. doi:10.1007/BF02714140
   PubMed Web of Science ®Google Scholar
• Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine. 2017;99(May):281. doi:10.1016/j.cyto.2017.08.005
   PubMedGoogle Scholar
• Guan WJ, Gao YH, Xu G, et al. Bronchodilator response in adults with bronchiectasis: correlation with clinical parameters and prognostic implications. J Thorac Dis. 2016;8(1):14–23. doi:10.3978/j.issn.2072-1439.2016.01.05
   PubMed Web of Science ®Google Scholar
• Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, PerpiñáTordera M. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461–468. doi:10.1378/chest.11-0180
   PubMed Web of Science ®Google Scholar
• Wong C, Chang C, Lewis C, et al. Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial. In: airway Pharmacology and Treatment [Internet]. Eur Respir Soc. 2017;PA1809.
   Web of Science ®Google Scholar
• Visser SK, Bye PTP, Fox GJ, et al. Management of Australian adults with bronchiectasis in tertiary care: evidence-based or access-driven? Lung. 2019;197(6):803–810. doi:10.1007/s00408-019-00280-x
   PubMed Web of Science ®Google Scholar
• Henkle E, Aksamit TR, Barker AF, et al. Pharmacotherapy for non-cystic fibrosis bronchiectasis: results from an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017;152(6):1120–1127. doi:10.1016/j.chest.2017.04.167
   PubMed Web of Science ®Google Scholar
• Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623–1632. doi:10.1016/j.rmed.2005.12.002
   PubMed Web of Science ®Google Scholar
• Aliberti S, Sotgiu G, Blasi F, Saderi L, Posadas T, Martinez Garcia MA. Blood eosinophils predict inhaled fluticasone response in bronchiectasis. Eur Respir J. 2020;56(2):2000453. doi:10.1183/13993003.00453-2020
   PubMed Web of Science ®Google Scholar
• Hernando R, Drobnic ME, Cruz MJ, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis. Int J Clin Pharm. 2012;34(4):644–650. doi:10.1007/s11096-012-9659-6
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116(1):40–46. doi:10.1378/chest.116.1.40
   PubMed Web of Science ®Google Scholar
• Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):853–860. doi:10.1164/rccm.200709-1413OC
   PubMed Web of Science ®Google Scholar
• Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J. 1996;9(8):1601–1604. doi:10.1183/09031936.96.09081601
   PubMed Web of Science ®Google Scholar
• Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974–979. doi:10.1183/09031936.06.00074605
   PubMed Web of Science ®Google Scholar
• Oshagbemi OA, Odiba JO, Daniel A, Yunusa I. Absolute blood eosinophil counts to guide inhaled corticosteroids therapy among patients with COPD: systematic review and meta-analysis. Curr Drug Targets. 2019;20(16):1670–1679. doi:10.2174/1389450120666190808141625
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018;52(6):6–8. doi:10.1183/13993003.01230-2018
   Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332. doi:10.1056/NEJM200008033430504
   PubMed Web of Science ®Google Scholar
• O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J. 2019;54(1):1–14. doi:10.1183/13993003.00491-2019
   Web of Science ®Google Scholar
• Kuprys-Lipinska I, Kolacinska-Flont M, Kuna P. New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines? Clin Transl Allergy. 2020;10(1):1–14. doi:10.1186/s13601-020-00316-z
   PubMed Web of Science ®Google Scholar
• Henkle E, Curtis JR, Chen L, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019;54(1). doi:10.1183/13993003.01896-2018
   PubMed Web of Science ®Google Scholar